Vilanterol is prescribed for:
- Asthma maintenance (in combination)
- COPD maintenance
- Respiratory disease management
Only available in combination products, not as monotherapy.
Generic Name: Vilanterol
Brand Names: Breo Ellipta (with fluticasone), Anoro Ellipta (with umeclidinium)
Vilanterol is a once-daily long-acting beta-agonist available in combination inhalers for asthma and COPD.
Vilanterol is prescribed for:
Only available in combination products, not as monotherapy.
Common side effects:
Serious side effects similar to other LABAs.
Vilanterol is a once-daily LABA that provides 24-hour bronchodilation.
Available as:
The 24-hour duration improves adherence compared to twice-daily LABAs.
For more information, visit the manufacturer's website.
This medication is commonly used to treat or manage the following conditions:
Asthma, a chronic lung disease, causes airway inflammation and narrowing, resulting in wheezing, coughing, and shortness of breath, triggered by allergens, irritants, infections, or stress.
COPD, a progressive lung disease causing irreversible airflow limitation, encompassing emphysema and chronic bronchitis, is primarily driven by irritant exposure like smoking, leading to shortness of breath and chronic cough.
Osteoarthritis, a common degenerative joint disease, causes pain, stiffness, and reduced motion due to cartilage breakdown from aging, genetics, obesity, injuries, or repetitive stress.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Vilanterol? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.